NFE2L2 and early-onset autosomal dominant Alzheimer disease: Therefore, it is likely that the increase in NRF2 signaling pathway predominantly takes place in astrocytes/microglia, as is the case in other pathologies, such as Parkinson’s and Alzheimer’s diseases [20,23,43].